Provided by Tiger Trade Technology Pte. Ltd.

Elicio Therapeutics

1.94
+0.12016.60%
Volume:237.26K
Turnover:452.98K
Market Cap:50.99M
PE:-0.89
High:1.96
Open:1.82
Low:1.82
Close:1.82
52wk High:16.00
52wk Low:1.71
Shares:26.28M
Float Shares:19.19M
Volume Ratio:0.91
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1721
EPS(LYR):-2.5842
ROE:-774.56%
ROA:-77.88%
PB:6.42
PE(LYR):-0.75

Loading ...

Elicio Therapeutics Inc : B. Riley Cuts Target Price to $8 from $27

THOMSON REUTERS
·
Sep 24

Elicio Says Phase 2 Amplify-7P Pancreatic Cancer Data for ELI-002 7P Earns Late-Breaking Oral Slot at ESMO 2026

Reuters
·
Sep 24

Elicio Therapeutics Announces Late-Breaking Phase 2 Amplify-7P Data Selected for Proffered Paper Oral Presentation at Esmo Congress 2026

THOMSON REUTERS
·
Sep 24

B. Riley Adjusts Price Target on Elicio Therapeutics to $8 From $27, Keeps Buy Rating

MT Newswires Live
·
Sep 24

Elicio Therapeutics Sets Key 2026 Shareholder Proposal Deadlines

TIPRANKS
·
Sep 15

Elicio Therapeutics CEO, CSO to Join H.C. Wainwright Global Investment Conference Fireside Chat

Reuters
·
Aug 31

Elicio Therapeutics to Hold One-on-One Investor Meetings at Wells Fargo Healthcare Conference

Reuters
·
Aug 24

Elicio Therapeutics Price Target Maintained with a $23.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 18

Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate

Benzinga Earnings
·
Aug 14

Elicio Therapeutics Q2 Net Loss Narrows as R&D Expenses Fall

Reuters
·
Aug 14

Elicio Therapeutics Q2 Basic EPS USD -0.43

THOMSON REUTERS
·
Aug 14

Elicio Therapeutics Q2 Income from Operations USD -10.429 Million

THOMSON REUTERS
·
Aug 14

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

GlobeNewswire
·
Aug 14

Elicio Opens Phase 1 Neoadjuvant ELI-002 7P Trial in Resectable Pancreatic Cancer at MSK

Reuters
·
Aug 10

Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant Eli-002 7P for Pancreatic Ductal Adenocarcinoma

THOMSON REUTERS
·
Aug 10

Elicio Therapeutics - Study Expected to Enroll 20 Patients with Resectable or Borderline Resectable Pdac

THOMSON REUTERS
·
Aug 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 07

Elicio Therapeutics Inc Expected to Post a Loss of 54 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Elicio Therapeutics Closes $15 Million Registered Direct Offering

MT Newswires Live
·
Jul 07

Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering

THOMSON REUTERS
·
Jul 07